Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01670032 · ClinicalTrials.gov registry record · Phase 2
Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo
A Phase 2 study, sponsored by NovaBay Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 328
- Enrollment target
NCT01670032 is a Phase 2 study that has completed, run by NovaBay Pharmaceuticals. The registered enrollment target is 328 participants.
The verdict
NCT01670032, a Phase 2 study, has completed, sponsored by NovaBay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 328 participants
- Enrollment target
Study Summary
This study will be a multicenter, randomized, vehicle controlled, parallel, group, double blind study. Eligible subjects with a clinical diagnosis of impetigo will be randomized to one of four treatment groups: 1.5% CD07223 Topical Gel applied BID; 1.5% CD07223 Topical Gel applied TID; Vehicle Topical Gel applied BID;Vehicle Topical Gel applied TID. All treatments will be administered for 7 days. Disease activity for the Target Lesion will be evaluated using the Skin Infection Rating Scale (SIRS) Score.
Interventions
- DRUG Experimental: CD07223 1.5 % Topical Gel BID
- DRUG Experimental: CD07223 1.5% Topical Gel TID
- DRUG Placebo Comparator: CD07223 vehicle gel BID
- DRUG Placebo Comparator: CD07223 vehicle gel TID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01670032
The ClinicalTrials.gov registry entry for NCT01670032 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 328 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NovaBay Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Experimental: CD07223 1.5 % Topical Gel BID is the first listed.
NCT01670032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01670032 about?
NCT01670032 is a clinical study titled "Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo". This study will be a multicenter, randomized, vehicle controlled, parallel, group, double blind study. Eligible subjects with a clinical diagnosis of impetigo will be randomized to one of four treatment groups: 1.5% CD07223 Topical Gel applied BID; 1.5% CD07223 Topical Gel applied TID; Vehicle Topic...
What is the current status of trial NCT01670032?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 328 participants. The study started on 2012-08. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01670032?
The interventions under investigation include: Experimental: CD07223 1.5 % Topical Gel BID (DRUG), Experimental: CD07223 1.5% Topical Gel TID (DRUG), Placebo Comparator: CD07223 vehicle gel BID (DRUG), Placebo Comparator: CD07223 vehicle gel TID (DRUG).
Who is sponsoring clinical trial NCT01670032?
This trial is sponsored by NovaBay Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.